Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16688539 | 0.81 | NPC1 (0.49) | CNR2APEX1 | |
| SCHEMBL13361521 | 0.79 | S1PR2 (0.58) | MAPTTSHR | |
| SCHEMBL3312105 | 0.79 | S1PR2 (0.71) | MAPT | |
| SCHEMBL6514398 | 0.78 | ALDH1A1 (0.54) | KDM4E | |
| SCHEMBL3312112 | 0.77 | S1PR2 (0.48) | MAPT | |
| SCHEMBL18180338 | 0.77 | APEX1 (0.73) | CNR2MAPTAPEX1KDM4E | |
| SCHEMBL22068701 | 0.77 | POLB (0.52) | CNR2TSHR | |
| SCHEMBL27767304 | 0.76 | APEX1 (0.47) | CNR2MAPTAPEX1KDM4E | |
| SCHEMBL24822482 | 0.76 | CNR2 (0.48) | CNR2 | |
| SCHEMBL30320111 | 0.75 | APEX1 (0.61) | MAPTAPEX1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| CN-101622234-B | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG | 2013-08-07 | — | — | CN | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
| CN-101622234-A | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG | 2010-01-06 | — | — | CN | disclosed |
| EP-2132186-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | Novartis AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107436-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | CNR2 48/4885MAPT 3853/4885APEX1 4035/4885 |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | CNR2 52/4885MAPT 4020/4885APEX1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.